Literature DB >> 30877212

Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018.

Sibel Z Aydin1,2, Joanna C Robson1,2, Antoine G Sreih1,2, Catherine Hill1,2, Fatma Alibaz-Oner1,2, Sarah Mackie1,2, Susan Beard1,2, Ahmet Gul1,2, Gülen Hatemi1,2, Tanaz A Kermani1,2, Alfred Mahr1,2, Alexa Meara1,2, Nataliya Milman1,2, Beverley Shea1,2, Gunnar Tómasson1,2, Peter Tugwell1,2, Haner Direskeneli1,2, Peter A Merkel3,4.   

Abstract

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV).
METHODS: An international Delphi exercise conducted among investigators identified items considered important to measure active disease. In parallel, qualitative research with patients was conducted, including interviews and focus groups.
RESULTS: Next steps prioritized by the group for LVV include (1) defining disease states (remission, flare, and patient-acceptable symptom state) and (2) selection of patient-reported outcome tools.
CONCLUSION: The ultimate goal is to develop an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV.

Entities:  

Keywords:  GIANT CELL ARTERITIS; LARGE-VESSEL VASCULITIS; OMERACT; OUTCOMES; TAKAYASU ARTERITIS; VASCULITIS

Mesh:

Year:  2019        PMID: 30877212      PMCID: PMC7254610          DOI: 10.3899/jrheum.181072

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

Review 1.  Large-vessel vasculitis.

Authors:  Philip Seo; John H Stone
Journal:  Arthritis Rheum       Date:  2004-02-15

2.  Quality of life of patients treated for giant cell arteritis: a case-control study.

Authors:  Stéphanie Jobard; Julie Magnant; Hélène Blasco; Nicole Ferreira-Maldent; Isabelle Griffoul; Elisabeth Diot; François Maillot
Journal:  Clin Rheumatol       Date:  2017-04-12       Impact factor: 2.980

3.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

4.  Patient-reported outcomes in Takayasu's arteritis.

Authors:  Fatma Alibaz-Oner; Antoine G Sreih; Peter A Merkel; Haner Direskeneli
Journal:  Presse Med       Date:  2017-07-26       Impact factor: 1.228

5.  Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu.

Authors:  Sibel Z Aydin; Neslihan Yilmaz; Servet Akar; Kenan Aksu; Sevil Kamali; Eftal Yucel; Omer Karadag; Muge Bicakcigil; Huseyin Ozer; Sedat Kiraz; Fatos Onen; Murat Inanc; Gokhan Keser; Nurullah Akkoc; Haner Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2010-06-11       Impact factor: 7.580

6.  Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score.

Authors:  Fatma Alibaz-Oner; Sibel Z Aydin; Servet Akar; Kenan Aksu; Sevil Kamali; Eftal Yucel; Omer Karadag; Huseyin Ozer; Sedat Kiraz; Fatos Onen; Murat Inanc; Gokhan Keser; Nurullah Akkoc; Haner Direskeneli
Journal:  J Rheumatol       Date:  2015-07-01       Impact factor: 4.666

Review 7.  Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.

Authors:  Sibel Zehra Aydin; Haner Direskeneli; Antoine Sreih; Fatma Alibaz-Oner; Ahmet Gul; Sevil Kamali; Gulen Hatemi; Tanaz Kermani; Sarah L Mackie; Alfred Mahr; Alexa Meara; Nataliya Milman; Heidi Nugent; Joanna Robson; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

8.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

9.  Impaired quality of life, disability and mental health in Takayasu's arteritis.

Authors:  Neslihan Yilmaz; Meryem Can; Fatma Alibaz Oner; Melike Kalfa; Hakan Emmungil; Omer Karadag; Fatih Yildiz; Gezmis Kimyon; Baris Yilmazer; Vedat Gerdan; Sule Yasar Bilge; Birkan Ilhan; Veli Cobankara; Timucin Kasifoglu; Ayse Cefle; Bunyamin Kisacik; Ahmet Mesut Onat; Servet Akar; Fatos Onen; Eren Erken; Sedat Kiraz; Kenan Aksu; Gokhan Keser; Gonca Mumcu; Haner Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2013-07-19       Impact factor: 7.580

10.  Health-related outcomes of importance to patients with Takayasu's arteritis.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Ebony Easley; Trocon Davis; Gonca Mumcu; Nataliya Milman; Joanna Robson; Haner Direskeneli; Peter A Merkel; Peter Cronholm
Journal:  Clin Exp Rheumatol       Date:  2017-09-18       Impact factor: 4.473

View more
  2 in total

1.  Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis.

Authors:  Kaitlin A Quinn; Hugh D Alessi; Cristina Ponte; Emily Rose; Mark A Ahlman; Christopher Redmond; Yiming Luo; Ertugrul Cagri Bolek; Carol A Langford; Peter A Merkel; Peter C Grayson
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

Review 2.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.